Who
Kevin F. McLaughlin
Director
Company insider
Files Form 4 as: Director, Vericel; Director, Invivyd; Director, Decibel Therapeutics; SVP, CFO and Treasurer, Acceleron Pharma; President and CEO, Praecis Pharmaceuticals.
In numbers
- Trades disclosed
- 392
- Buys
- 1
- Sells
- 55
- Bought
- $125K
- Sold
- $32.4M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 1 Sep 2006
- Last trade
- 12 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 14 Aug 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $91K7,000 at $13.05 | filing |
| 12 Aug 2026filed 14 Aug 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $312K7,000 at $44.53 | filing |
| 12 Aug 2026filed 14 Aug 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —7,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —7,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $91K7,000 at $13.05 | filing |
| 12 Aug 2026filed 14 Aug 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $312K7,000 at $44.53 | filing |
| 19 May 2026filed 21 May 2026 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $9,2053,500 at $2.63 | filing |
| 13 May 2026filed 15 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $115K3,500 at $32.83 | filing |
| 13 May 2026filed 15 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $46K3,500 at $13.05 | filing |
| 13 May 2026filed 15 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $115K3,500 at $32.82 | filing |
| 13 May 2026filed 15 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $9,2053,500 at $2.63 | filing |
| 13 May 2026filed 15 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $115K3,500 at $32.83 | filing |
| 13 May 2026filed 15 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | $46K3,500 at $13.05 | filing |
| 13 May 2026filed 15 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $115K3,500 at $32.82 | filing |
News
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026IVVD · manilatimes.net · 21 Oct 2026Invivyd (NASDAQ:IVVD) and Arcus Biosciences (NYSE:RCUS) Critical ContrastIVVD · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Kevin F. McLaughlin; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.